Breast magnetic resonance imaging (MRI) surveillance in breast cancer survivors

被引:41
作者
Weinstock, Chana [1 ]
Campassi, Cristina [1 ]
Goloubeva, Olga [1 ]
Wooten, Kathleen [1 ]
Kesmodel, Susan [1 ]
Bellevance, Emily [1 ]
Feigenberg, Steven [1 ]
Ioffe, Olga [1 ]
Tkaczuk, Katherine H. R. [1 ]
机构
[1] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
关键词
Breast cancer; Magnetic resonance imaging; Bilateral; Surveillance; PROSPECTIVE MULTICENTER COHORT; HIGH FAMILIAL RISK; PERSONAL HISTORY; MAMMOGRAPHIC SURVEILLANCE; CONSERVATION TREATMENT; WOMEN; PATTERNS; ULTRASOUND; THERAPY; 1ST;
D O I
10.1186/s40064-015-1158-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose: As the breast cancer survivor population increases, the topic of screening these women for recurrences is increasingly relevant. In our institution, we use both breast MRI and mammography in the surveillance of breast cancer survivors, although little data exists on the use of MRI in this setting. We present a retrospective analysis of our experience and compare the sensitivity and specificity of MRI vs. mammography in this setting. Methods: We identified women under 65 with a history of breast cancer and at least one follow-up MRI performed along with a mammogram done within 6 months of the MRI. We compared the outcomes of MRI and mammography in terms of biopsies performed as well as in detection of new cancers. Results: Of 617 charts reviewed, 249 patients met inclusion criteria, with 571 paired MRI/mammogram results. There were 27 biopsies performed due to MRI findings alone, 10 done due to mammographic findings alone, and 15 done based on abnormalities seen on both imaging modalities. There were 8 malignancies identified based on an abnormal MRI, 3 detected on both MRI and mammography, and none identified via mammography alone. Overall, MRI had a sensitivity of 84.6% (the 95% CI 54.6-98.1) and a specificity of 95.3% (the 95% CI 93.3-96.9); mammography a sensitivity of 23.1% (the 95% CI 5.0-53.8), and a specificity of 96.4% (the 95% CI 94.5-97.8). Conclusions: Breast MRI is a useful surveillance modality in breast cancer survivors and may be more sensitive at detecting recurrences than mammography alone in this population.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 42 条
[1]  
[Anonymous], 2014, CANC TREATMENT SURVI
[2]  
[Anonymous], 2014, CANC BREAST SEER STA
[3]  
[Anonymous], AISS ADV INFORM SCI
[4]   What is achieved by mammographic surveillance after breast conservation treatment for breast cancer? [J].
Ashkanani, F ;
Sarkar, T ;
Needham, G ;
Coldwells, A ;
Ah-See, AK ;
Gilbert, FJ ;
Hutcheon, AW ;
Eremin, O ;
Heys, SD .
AMERICAN JOURNAL OF SURGERY, 2001, 182 (03) :207-210
[5]   Breast MRI Screening of Women With a Personal History of Breast Cancer [J].
Brennan, Sandra ;
Liberman, Laura ;
Dershaw, D. David ;
Morris, Elizabeth .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2010, 195 (02) :510-516
[6]   Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].
Carey, Lisa A. ;
Perou, Charles M. ;
Livasy, Chad A. ;
Dressler, Lynn G. ;
Cowan, David ;
Conway, Kathleen ;
Karaca, Gamze ;
Troester, Melissa A. ;
Tse, Chiu Kit ;
Edmiston, Sharon ;
Deming, Sandra L. ;
Geradts, Joseph ;
Cheang, Maggie C. U. ;
Nielsen, Torsten O. ;
Moorman, Patricia G. ;
Earp, H. Shelton ;
Millikan, Robert C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502
[7]  
Carney PA, 2003, ANN INTERN MED, V138, P168, DOI 10.7326/0003-4819-138-3-200302040-00008
[8]  
Chen Y, 1999, CANCER EPIDEM BIOMAR, V8, P855
[9]   Effectiveness of Screening With Annual Magnetic Resonance Imaging and Mammography: Results of the Initial Screen From the Ontario High Risk Breast Screening Program [J].
Chiarelli, Anna M. ;
Prummel, Maegan V. ;
Muradali, Derek ;
Majpruz, Vicky ;
Horgan, Meaghan ;
Carroll, June C. ;
Eisen, Andrea ;
Meschino, Wendy S. ;
Shumak, Rene S. ;
Warner, Ellen ;
Rabeneck, Linda .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (21) :2224-2230
[10]   Racial and ethnic differences in breast cancer survival - How much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? [J].
Curtis, Elana ;
Quale, Chris ;
Haggstrorn, David ;
Smith-Bindman, Rebecca .
CANCER, 2008, 112 (01) :171-180